A7856
Acipimox
≥99% (TLC)
Synonym(s):
2-Carboxy-5-methylpyrazine 4-oxide, 5-Methylpyrazinecarboxylic acid 4-oxide
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C6H6N2O3
CAS Number:
Molecular Weight:
154.12
EC Number:
MDL number:
UNSPSC Code:
12352205
NACRES:
NA.79
Pricing and availability is not currently available.
Recommended Products
Quality Level
assay
≥99% (TLC)
form
powder
color
off-white to faint yellow
mp
177-180 °C
storage temp.
2-8°C
SMILES string
[n+]1(c(cncc1C(=O)O)C)[O-]
InChI
1S/C6H6N2O3/c1-4-2-7-3-5(6(9)10)8(4)11/h2-3H,1H3,(H,9,10)
InChI key
DNRXJHATQULEHC-UHFFFAOYSA-N
Related Categories
Biochem/physiol Actions
Acipimox, also known as olbemox,[1] is a nicotinic acid analog.[2] It functions as an anti-lipolytic drug[3] and vasodilator. Acipimox may be used in various metabolic studies involving insulin and ghrelin.[4] It lowers total cholesterol and total triglycerides, which helps in the treatment of hyperlipidemia.[2]
Niacin-derived, vasodilator studied for its lipid-lowering effect.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Mads Halbirk et al.
American journal of physiology. Heart and circulatory physiology, 299(4), H1220-H1225 (2010-08-17)
Circulating free fatty acids (FFAs) may worsen heart failure (HF) due to myocardial lipotoxicity and impaired energy generation. We studied cardiac and whole body effects of 28 days of suppression of circulating FFAs with acipimox in patients with chronic HF.
Fabrizio Montecucco et al.
American journal of physiology. Endocrinology and metabolism, 300(4), E681-E690 (2011-01-27)
Metabolic syndrome is a proatherosclerotic condition clustering cardiovascular risk factors, including glucose and lipid profile alterations. The pathophysiological mechanisms favoring atherosclerotic inflammation in the metabolic syndrome remain elusive. Here, we investigated the potential role of the antilipolytic drug acipimox on
Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression
Cordido F, et al.
The Journal of clinical endocrinology and metabolism, 81(3), 914-918 (1996)
Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia
Taskinen MR and Nikkila EA
Atherosclerosis, 69(2-3), 249-255 (1988)
J Huang et al.
Drug research, 63(2), 79-83 (2013-03-01)
The study was designed to compare the pharmacokinetic parameters and relative bioavailability of a newly generic acipimox 250-mg tablets (test formulation) with a branded 250-mg tablets (reference formulation). A single-dose, randomized-sequence, 2-way crossover study was conducted in 20 healthy Chinese
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
